Establishment Labs (ESTA) announced that it has submitted Motiva implants for approval in primary and revision breast reconstruction to the FDA. The products were previously approved by the FDA for use in breast augmentation on September 27, 2024.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESTA:
- Establishment Labs price target raised to $85 from $72 at Canaccord
- Establishment Labs price target raised to $90 from $85 at Mizuho
- Establishment Labs Holdings: Strategic Growth and Profitability Prospects Reinforce Buy Rating
- Establishment Labs price target raised to $75 from $62 at Citi
- Establishment Labs price target raised to $84 from $70 at Needham